Explore. Grow. Launch.
A resource for entrepreneurs and founders of in various stages of growth, WilmerHale Launch is your source for answers to the questions that impact you every day. We provide the tools and information you need to build your knowledge and position your for success.
Start ExploringExplore Topics Related to Your Business
Formation
New to the startup world or a seasoned entrepreneur in need of a refresher? Explore our formation topics to ensure your business is built for the long haul.
Read MoreFinancing
Whether you’re flush with cash or in need of additional financing, understanding all of your financial options will set you up for the best chance of meeting your goals.
Read MoreIP
Protecting your IP is critical to your company’s future. Ensuring you file necessary patents, obtain trademarks and secure copyright protection can be the difference between failure and success.
Read MoreRelated Topics
Expansion
Time to take your business to the next level? Increase your knowledge on what it will take to grow your business, whether in the US or abroad.
Read MoreRelated Topics
Let our Knowledge Navigator direct you to content specific to where you are on your journey.
Build Your Knowledge with Our Tools
Startup Dictionary
Understand the jargon by perusing our comprehensive glossary of business terms.
Find Out MoreKnowledge Navigator
Let our interactive tool direct you to answers specific to your business situation.
Find Out MoreDocument Generator
Create important legal documents that will enable you to start and grow your company.
Find Out MoreThis online tool built and operated by a third party helps founders make decisions on how to divide equity.
Find Out MoreQ&A Forum
View our extensive list of common startup-related questions answered by our legal team.
Find Out MoreResearch News and Information
News & Publications
WilmerHale Represents Volastra Therapeutics in $60M Series A Financing
3.9.2023
WilmerHale represented Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), in closing its $60 million Series A financing, which was led by founding investors Polaris Partners and ARCH Venture Partners alongside Eli Lilly and Company.
Read MoreVideos
Watch WilmerHale lawyers and industry experts speak about topics pertaining to your business.
Watch Videos